Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis. J of Skin 2017, 1 (3.1), s12. https://doi.org/10.25251/skin.1.supp.11.